Alpine Immune Sciences Amends Previously Announced 2020 Option And License Agreement With AbbVie For Acazicolcept
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences has amended its 2020 agreement with AbbVie regarding acazicolcept. The amendment halts new enrollment in the phase 2 study for systemic lupus erythematosus. Final analysis is expected by end of 2024. AbbVie retains an option to license acazicolcept, exercisable upon receiving a data package from Alpine.
December 21, 2023 | 9:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie retains an exclusive option to license acazicolcept from Alpine Immune Sciences, with the option exercisable upon delivery of a data package.
For AbbVie, the amendment is a neutral event in the short term as it maintains the status quo. The option to license acazicolcept provides flexibility and potential for future investment but does not immediately impact the company's operations or financials.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
NEUTRAL IMPACT
Alpine Immune Sciences amends its agreement with AbbVie, stopping new enrollment for acazicolcept's phase 2 study. Final study results are expected by the end of 2024.
The amendment may be seen as a neutral to slightly negative development for Alpine Immune Sciences in the short term, as it indicates a pause in the study's progression. However, the retention of AbbVie's licensing option suggests there is still potential for future positive developments.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80